Ergomed plc Ergomed expands operations in Japan (5135W)
26 Abril 2021 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 5135W
Ergomed plc
26 April 2021
RNS
PRESS RELEASE
Ergomed expands operations in Japan
New legal entity and regional office established in Tokyo
responding to client demand
Guildford, UK - 26 April 2021 : Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry , announces
that its PrimeVigilance business, a global leader in the provision
of pharmacovigilance and medical information services, has
established its new legal entity and regional office in Japan and
is fully operational from 26 April 2021.
The new subsidiary company, trading as PrimeVigilance Japan KK,
is based in Tokyo and offers a comprehensive range of
pharmacovigilance services, including a dedicated Japanese safety
database. Full Japanese language Medical Information services are
also provided.
This expansion provides existing and prospective international
PrimeVigilance clients the opportunity to extend their product
coverage into the strategically important Japanese pharmaceutical
market, the fourth largest globally after the US, the EU and China.
It also provides PrimeVigilance and Ergomed the opportunity to
provide high quality specialist services to domestic Japanese
companies, opening up a new market.
PrimeVigilance has a strong operational presence in Europe and
the recent acquisitions of Ashfield PV and MedSource, as well as
significant organic growth in the US, have elevated PrimeVigilance
into a market leading position in North America. The new facility
in Japan adds Asia to Ergomed's global footprint, enabling
PrimeVigilance to offer operational services in all major regions,
with pharmacovigilance and medical information professionals based
in each territory, providing both local and global expertise.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said :
"Ergomed has provided a breadth of services and expertise in Asia
both as a CRO and as a pharmacovigilance specialist through its
outsourcing model for many years. With a solid base of
international clients in Japan, Ergomed is establishing its own
pharmacovigilance and medical information infrastructure to serve
current and future clients and further strengthen our global
operational and commercial footprint in the strategically important
Asia region. Following the two US acquisitions in 2020 of Ashfield
Pharmacovigilance (now PrimeVigilance USA) and MedSource, this
marks another major step in our strategy to establish Ergomed as a
leading international pharmaceutical services specialist."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Freddie Barnfield / Matthew O'Dowd
(Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Olivia Manser / Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical trials, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes a full range of high-quality
contract research and clinical trial management (CRO) services
under the Ergomed brand together with an industry-leading suite of
specialist pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, and an internationally recognized specialist
expertise in orphan drug development, under the PSR brand. For
further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDBGDSLDDDGBU
(END) Dow Jones Newswires
April 26, 2021 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024